AgomAb Therapeutics NV Form 4 Filing
AgomAb Therapeutics NV reported a Form 4 filing on November 6, 2026, regarding activity from November 5, 2026, filed by David R. Epstein.
Stocks · News reference
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Kodiak AI Reports Third Quarter 2026 Financial Results and Operational Milestones
Kodiak AI announced its Q3 2026 financial results, highlighting a 286% year-over-year revenue increase and significant progress toward its year-end unsupervised autonomous long-haul launch.
UPDATE: Kodiak AI Q3 EPS $0.09 Beats $(0.24) Estimate, Sales $2.970M Beat $2.467M Estimate
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apnimed, Inc. announced the issuance of equity-based inducement grants to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
Agomab Therapeutics Announces Participation in Upcoming Investor Conferences
Agomab Therapeutics NV announced that its management team will participate in several upcoming healthcare investor conferences throughout November and December 2026.
JBT Marel Corporation Files Third Quarter 2026 Form 10-Q
JBT Marel Corporation has officially filed its Form 10-Q for the third quarter of 2026.